Yong Hyu Jeong1, Choong-Kun Lee2, Kwanhyeong Jo1, Sang Hyun Hwang1, Jongtae Cha1, Jeong Won Lee1, Mijin Yun1, Arthur Cho1. 1. Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, 120-752 Seoul South Korea. 2. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, 120-752 Seoul South Korea.
Abstract
PURPOSE: The aim of this study was to determine the relationship between [(18)]-2-fluoro-2-deoxy-D-glucose (FDG) uptake and excision repair cross-complementation group 1 (ERCC-1) expression and to evaluate the prognostic effect of these two factors in resectable non-small cell lung cancer (NSCLC) patients. METHODS: We retrospectively reviewed 212 patients with resectable NSCLC who underwent FDG positron emission tomography/computed tomography (PET/CT) scan for cancer staging and ERCC-1 expression analysis between January 2008 to December 2011. All patients were then followed-up for survival analysis. Semiquantitative evaluation of ERCC-1 was performed with the H-scoring system and was correlated with maximum standardized uptake value (SUVmax) of NSCLC. Univariate and multivariate analyses were performed to evaluate for FDG uptake and ERCC-1 expression predicting overall survival. RESULTS: In 212 patients (139 male, median age 68 ± 9.11), 112 patients had ERCC-positive tumors and 100 patients had ERCC-negative tumors. There was no significant difference in SUVmax between ERCC-1-positive tumors (8.02 ± 5.40) and ERCC-1-negative tumors (7.57 ± 6.56, p = 0.584). All patients were followed-up for a median of 40.5 months (95 % confidence interval [CI], 38.5-42.2 months). Univariate analysis and multivariate analysis for all patients showed that both ERCC-1 expression (hazard ratio [HR], 2.78; 95 % CI, 1.20-6.47) and FDG uptake (HR, 4.50; 95 % CI, 2.07-9.77) independently predicted overall survival. CONCLUSIONS: We have found no statistical correlation between FDG uptake and ERCC-1 expression in NSCLC. However, both higher FDG uptake and positive ERCC-1 expression are independent predictive markers of prognosis, suggesting that both should be obtained during patient workup.
PURPOSE: The aim of this study was to determine the relationship between [(18)]-2-fluoro-2-deoxy-D-glucose (FDG) uptake and excision repair cross-complementation group 1 (ERCC-1) expression and to evaluate the prognostic effect of these two factors in resectable non-small cell lung cancer (NSCLC) patients. METHODS: We retrospectively reviewed 212 patients with resectable NSCLC who underwent FDG positron emission tomography/computed tomography (PET/CT) scan for cancer staging and ERCC-1 expression analysis between January 2008 to December 2011. All patients were then followed-up for survival analysis. Semiquantitative evaluation of ERCC-1 was performed with the H-scoring system and was correlated with maximum standardized uptake value (SUVmax) of NSCLC. Univariate and multivariate analyses were performed to evaluate for FDG uptake and ERCC-1 expression predicting overall survival. RESULTS: In 212 patients (139 male, median age 68 ± 9.11), 112 patients had ERCC-positive tumors and 100 patients had ERCC-negative tumors. There was no significant difference in SUVmax between ERCC-1-positive tumors (8.02 ± 5.40) and ERCC-1-negative tumors (7.57 ± 6.56, p = 0.584). All patients were followed-up for a median of 40.5 months (95 % confidence interval [CI], 38.5-42.2 months). Univariate analysis and multivariate analysis for all patients showed that both ERCC-1 expression (hazard ratio [HR], 2.78; 95 % CI, 1.20-6.47) and FDG uptake (HR, 4.50; 95 % CI, 2.07-9.77) independently predicted overall survival. CONCLUSIONS: We have found no statistical correlation between FDG uptake and ERCC-1 expression in NSCLC. However, both higher FDG uptake and positive ERCC-1 expression are independent predictive markers of prognosis, suggesting that both should be obtained during patient workup.
Authors: J Bellmunt; L Paz-Ares; M Cuello; F L Cecere; S Albiol; V Guillem; E Gallardo; J Carles; P Mendez; J J de la Cruz; M Taron; R Rosell; J Baselga Journal: Ann Oncol Date: 2007-01-17 Impact factor: 32.976
Authors: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: P Ceppi; M Volante; S Novello; I Rapa; K D Danenberg; P V Danenberg; A Cambieri; G Selvaggi; S Saviozzi; R Calogero; M Papotti; G V Scagliotti Journal: Ann Oncol Date: 2006-09-15 Impact factor: 32.976
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: K Kaira; M Endo; T Shukuya; H Kenmotsu; T Naito; A Ono; A Tsuya; Y Nakamua; T Takahashi; H Murakami; H Kondo; T Nakajima; N Yamamoto Journal: Neoplasma Date: 2012 Impact factor: 2.575